Improving cancer treatment by targeting a specific protein to overcome drug resistance
Official title: Targeting p300 to Overcome PARP inhibitor resistance induced by acidic tumor microenvironment
Funded at University of Tx Md Anderson Can Ctr · NIH-10931368 · Data updated 2026-11-12
This study is looking at a new way to make ovarian cancer treatments work better for patients with BRCA1/2 mutations by combining two types of medicines to help overcome challenges caused by the tumor's environment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | September 19, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $340,366 |
| NIH project number | 5P50CA281701-02 |
| Project ID | NIH-10931368 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are ovarian cancer patients with BRCA1/2 mutations who are experiencing resistance to PARP inhibitors.
✕Less likely to help
Patients without BRCA1/2 mutations or those not affected by PARP inhibitor resistance may not benefit from this research.
What this research studies
This research aims to enhance the effectiveness of PARP inhibitors, which are used to treat certain types of ovarian cancer, particularly in patients with BRCA1/2 mutations. The focus is on overcoming resistance caused by the acidic environment of tumors by targeting an epigenetic regulator known as p300. The study will utilize a combination of a p300 inhibitor and PARP inhibitors to determine if this approach can improve treatment outcomes. Patients may benefit from a novel therapeutic strategy that addresses a significant challenge in cancer treatment.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for ovarian cancer patients who currently face resistance to existing therapies.
How similar studies have gone: Previous research has shown promise in targeting similar pathways to overcome drug resistance in cancer treatment, indicating potential for success in this novel approach.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Zhang, Rugang — University of Tx Md Anderson Can Ctr
- Study coordinator: Zhang, Rugang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.